NIP 022

Drug Profile

NIP 022

Alternative Names: NIP022; ONO-7746; YHI 1501

Latest Information Update: 18 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nissan Chemical Industries
  • Developer Nissan Chemical Industries; Yakult Honsha
  • Class Small molecules
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Thrombocytopenia

Most Recent Events

  • 01 Jun 2017 Yakult Honsha completes a phase I trial in Thrombocytopenia (In volunteers) in Japan (PO) (JapicCTI163296)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Thrombocytopenia(Chemotherapy-induced) in Russia (PO, Capsule)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Thrombocytopenia(Chemotherapy-induced) in South Korea (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top